Tevogen (TVGN) Research & Development (2023 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Research & Development came in at $3.1 million in Q1 2026, down 1.89% YoY from $3.2 million in Q1 2025, and up 48.87% on a QoQ basis from $2.1 million in Q4 2025.
Tevogen (TVGN) Research & Development (2023 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 4 years of Research & Development data on file, last reported at $3.1 million in Q1 2026.
- Quarterly Research & Development fell 1.89% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (down 17.63% YoY) and the FY2025 annual result came in at $11.1 million, down 64.19% from the prior year.
- Research & Development grew to $3.1 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $20.8 million in Q1 2024 to a low of $908049.0 in Q4 2023.
- A 4-year average of $3.8 million and a median of $2.8 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development soared 1444.83% — and 2025, when it slumped 84.65%.
- Tracing TVGN's Research & Development over 4 years: stood at $908049.0 in 2023, then surged by 212.35% to $2.8 million in 2024, then retreated by 25.76% to $2.1 million in 2025, then jumped by 48.87% to $3.1 million in 2026.
- The last three Research & Development figures came in at $3.1 million (Q1 2026), $2.1 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 97.90 Mn |
| 10 | Tevogen | 25.39 Mn | 25.39 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.13 Mn |
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 3.11 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Sep 30, 2024 | 3.26 Mn |
| Jun 30, 2024 | 4.12 Mn |
| Mar 31, 2024 | 20.81 Mn |
| Dec 31, 2023 | 908,049.00 |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 1.35 Mn |